Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Previously Presented) A compound of formula (I):



(I)

wherein:

A represents an optionally substituted aryl, or an optionally substituted 5- or 6-membered heterocyclyl ring, or an optionally substituted bicyclic heterocyclyl group;

B represents a phenyl or pyridyl ring;

Z represents O, S, SO, or SO_2;

R^1 represents CO_2H, CN, $CONR^5R^6$, CH_2CO_2H, optionally substituted SO_2alkyl, $SO_2NR^5R^6$, $NR^5CONR^5R^6$, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocyclyl;

R^{2a} and R^{2b} each independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO_2alkyl, SR^5, NO_2, optionally substituted aryl, $CONR^5R^6$ or optionally substituted heteroaryl;

R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally substituted by a group independently selected from NR^4, O and SO_n, wherein n is 0, 1 or 2; optionally substituted alkenyl; or optionally substituted alkynyl: or R^x represents optionally substituted alkenyl, optionally substituted CQ^aQ^b-heterocyclyl, optionally substituted CQ^aQ^b-bicyclic heterocyclyl or optionally substituted CQ^aQ^b-aryl;

R^4 represents hydrogen or an optionally substituted alkyl;
R^5 represents hydrogen or an optionally substituted alkyl;
R^6 represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO_2aryl, optionally substituted SO_2alkyl, optionally substituted SO_2heteroaryl, CN, optionally substituted CQ^aQ^baryl, optionally substituted CQ^aQ^bheteroaryl or COR^7;
R^7 represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;
R^8 and R^9 each independently represents hydrogen, chloro, fluoro, CF_3, C_{1-3}alkoxy or C_{1-3}alkyl;
Q^a and Q^b are each independently selected from hydrogen and CH_3;
wherein when A is a 6-membered ring the R^1 substituent and cyclopentene ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocyclyl group the R^1 substituent and cyclopentene ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;
and derivatives thereof.

2. (Previously Presented) A compound according to claim 1 wherein B is pyridyl.

3. (Previously Presented) A compound according to claim 1 which is a compound of formula (IA):



(IA)

wherein:
W, X, and Y each represent CR^{12} or N;
V represents CR^1, CR^{12} or N;

wherein at least two of W, X, Y and V is CR^{12}, and R^{12} is independently selected from hydrogen, halogen, CF_3, CH_3, NH_2, NHC_{1-6}alkyl, $NHCOC_{1-6}$alkyl, and SCH_3;
Q^1 and Q^2 each represents CH, or one of Q^1 and Q^2 is N and the other is CH;
R^1 is CO_2H, $CONR^5R^6$, CH_2CO_2H, SO_2C_{1-6}alkyl, $SO_2NR^5R^6$, $NR^5CONR^5R^6$, tetrazolyl or $COSO_2NR^5R^6$;
R^{2a} and R^{2b} are selected from hydrogen, halogen, optionally substituted C_{1-6}alkyl, and optionally substituted C_{1-6}alkoxy;
R^x represents optionally substituted C_{3-8}alkyl, optionally substituted C_{3-8}alkenyl, and optionally substituted CH_2phenyl;
R^5 is hydrogen or C_{1-4}alkyl;
R^6 is hydrogen, C_{1-4}alkyl or SO_2phenyl;
R^{12} is selected from hydrogen, halogen, NR^5R^6, NR^5COC_{1-6}alkyl, $NR^5SO_2C_{1-6}$alkyl, OR^5, SR^5, and optionally substituted C_{1-6}alkyl;
or derivatives thereof.

4. (Previously Presented) A compound according to claim 3 wherein one of Q^1 and Q^2 is N and the other is CH.

5. – 6. (Canceled).

7. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of~~ claim~~s~~ 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.

8. – 9. (Canceled).

10. (Currently Amended) A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE_2 at EP_1 receptors which comprises administering to said subject an effective amount of a compound according to ~~any one of~~ claim~~s~~ 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof.

11. (Currently Amended) A method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound according to ~~any one of~~ claim~~s~~ 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof.

12. (Currently Amended) A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to ~~any one of~~ claims 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof.

13. -15. (Canceled).

16. (New) The method of claim 10 wherein the subject is human.

17. (New) The method of claim 11 wherein the subject is human.

18. (New) The method of claim 12 wherein the subject is human.

19. (New) A method of mediating EP_1 receptors, comprising the step of administering an effective amount of a compound according to claim 1 or a pharmaceutically acceptable derivative thereof.